POSA39 Cost-Effectiveness Analysis of Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in Canada
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.185
https://www.valueinhealthjournal.com/article/S1098-3015(21)01980-X/fulltext
Title :
POSA39 Cost-Effectiveness Analysis of Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in Canada
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01980-X&doi=10.1016/j.jval.2021.11.185
First page :
Section Title :
Open access? :
No
Section Order :
10955